Q4 2024 Earnings Call Transcript March 31, 2025 Rani Therapeutics Holdings, Inc. misses on earnings expectations. Reported EPS is $-0.27 EPS, expectations were $-0.24. Operator: Welcome to the Rani ...

Currently, semaglutide is available exclusively as ... compared to tirzepatide and DAPIglutide in a diet-induced obese mouse mob. We believe this preservation of lean body mass could serve as ...

resulted in improved weight loss compared to semaglutide (Wegovy®) and cotadutide (another OXM analogue). Additionally, in pre-clinical mouse models, DA-1726 elicited similar weight reduction ...

With Semaglutide, postmenopausal women can achieve significant weight loss, improve insulin sensitivity, and lower the risk ...

Novo Nordisk filed for approval of an oral, 25-mg formulation of its weight loss blockbuster “earlier this year,” according ...

Tirzepatide linked to more GI issues than semaglutide in new study on weight-loss drugs without diabetes. Read more!

The researchers found that based on 551 cases, there were an estimated 24,499 emergency department visits attributed to semaglutide adverse events in 2022 through 2023 (mean patient age, 50.9 ...

Most common gastrointestinal issues seen were nausea/vomiting, abdominal pain, and diarrhea. HealthDay News — The rate of emergency department visits for adverse events among patients dispensed ...